drugset / Trial / NCT04862143

Pilot Decentralized Clinical Trial in Men and Pre and Post-menopausal Women With Breast Cancer and a Specific Mutation (PIK3CA) Treated With Alpelisib in Combination With Fulvestrant

NCT04862143

Phase 2 Terminated 2 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The study was designed to identify and register practical observations and experiences in connection with planning and implementing decentralized, patient-centered clinical trials at a geographic distance with virtual elements.

Timeline

Start
2022-03-08
Primary completion
2022-09-19
Completion
2022-09-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Alpelisib Small molecule 300 mg Oral
Subject Fulvestrant Small molecule 500 mg Intramuscular
Background Goserelin Other / unclassified 3.6 mg Intramuscular

Indications